Birtamimab in AL Amyloidosis: A Comprehensive Analysis of a Promising Amyloid Depleter from Post-Hoc Signal to Confirmatory Trial Failure

Executive Summary

Birtamimab (formerly NEOD001) is an investigational humanized IgG1 monoclonal antibody developed by Prothena Corporation for the treatment of light chain (AL) amyloidosis. The therapeutic was designed based on a compelling scientific rationale: to directly target and clear pathological amyloid deposits from vital organs, a mechanism complementary to standard-of-care therapies that only halt the production of new amyloidogenic proteins. This approach held particular promise for patients with advanced, Mayo Stage IV disease, for whom existing organ damage is the primary driver of a grim prognosis.

Birtamimab’s clinical development was a dramatic and ultimately cautionary tale. The initial Phase 3 VITAL trial was terminated early in 2018 for futility, as it failed to demonstrate a benefit in the broad population of AL amyloidosis patients. However, a subsequent post-hoc analysis of a small subgroup of Mayo Stage IV patients within VITAL revealed a striking and statistically significant survival benefit, prompting Prothena to resurrect the program in 2021. This led to the design of the confirmatory Phase 3 AFFIRM-AL trial, which focused exclusively on this high-risk patient population and was conducted under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA).

In May 2025, the AFFIRM-AL trial definitively failed, meeting neither its primary endpoint of improving all-cause mortality nor any of its secondary endpoints. The hazard ratio for mortality was near unity, indicating a complete lack of efficacy. In contrast to its efficacy failure, Birtamimab consistently demonstrated a favorable safety and tolerability profile across all clinical trials, with adverse event rates comparable to placebo.

The story of Birtamimab provides critical lessons for the biopharmaceutical industry. It serves as a textbook example of the statistical perils of basing major development decisions on post-hoc subgroup analyses. It also underscores the profound challenge of demonstrating a survival benefit in a frail patient population with a high background mortality rate. Despite its failure, Birtamimab’s journey has de-risked the general safety of the amyloid-depleter class and has reinforced the scientific rigor required to advance novel therapies. While this specific molecule did not succeed, the strategic imperative to develop therapies that clear existing amyloid deposits remains a critical and actively pursued goal in the management of AL amyloidosis.

---

Section 1: The Therapeutic Challenge of AL Amyloidosis and the Rationale for Amyloid Depletion

1.1 Pathophysiology of Light Chain (AL) Amyloidosis

Light chain (AL) amyloidosis is the most common form of systemic amyloidosis, a rare, progressive, and typically fatal plasma cell disorder.[1] The disease originates from a clonal population of plasma cells in the bone marrow, which produce excessive amounts of misfolded immunoglobulin light chains (LCs), either kappa (${\kappa}$) or lambda (${\lambda}$) isoforms.[2] These aberrant proteins fail to assemble into functional immunoglobulins and instead aggregate into soluble, toxic oligomers and, ultimately, insoluble, highly organized ${\beta}$-pleated sheet structures known as amyloid fibrils.[1]

These amyloid fibrils deposit extracellularly in vital organs and tissues, disrupting their normal architecture and function, which leads to progressive organ failure.[3] While AL amyloidosis can affect nearly any organ, the most commonly involved are the heart (approximately 80% of cases) and the kidneys (approximately 66% of cases).[2] Cardiac involvement is the most significant predictor of mortality, and the severity of organ damage dictates the patient's prognosis.[2]

The mortality risk is stratified using the revised 2012 Mayo Clinic Staging System, which categorizes patients from Stage I to IV based on cardiac biomarkers (troponin-T and NT-proBNP) and the level of circulating free light chains.[2] Patients with the most advanced disease, classified as Mayo Stage IV, have the highest risk of early mortality, with a median survival from diagnosis of only 5.8 months and a 5-year survival rate of just 14%.[2] This dire prognosis underscores the aggressive nature of the disease in its advanced stages.

1.2 The Limitations of the Current Standard of Care

The modern treatment paradigm for AL amyloidosis is centered on anti-plasma cell therapies designed to eliminate the underlying clonal source of the misfolded light chains.[1] The therapeutic goal is to achieve a rapid and deep hematologic response, thereby halting the production of new amyloidogenic precursors.[9] The therapies are largely adapted from those used to treat the related plasma cell malignancy, multiple myeloma.[8]

In 2021, the U.S. FDA approved the first-ever regimen for newly diagnosed AL amyloidosis: a four-drug combination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone (DaraCyborD).[8] This regimen, which combines an anti-CD38 monoclonal antibody with a proteasome inhibitor, an alkylating agent, and a corticosteroid, has become the standard of care (SoC) for eligible patients and can induce high rates of hematologic response.[8]

However, a critical limitation of this and all other anti-plasma cell strategies is that they do not address the pathology caused by pre-existing amyloid deposits.[13] These therapies effectively "turn off the factory" producing the toxic proteins but do nothing to remove the amyloid that has already accumulated and is actively causing organ damage.[14] For patients with advanced disease, particularly Mayo Stage IV with severe cardiac involvement, the existing amyloid burden is often so great that they succumb to organ failure before the benefits of halting new fibril formation can be realized. This creates a fundamental therapeutic gap, where the timeline of irreversible organ damage is often shorter than the timeline for SoC therapies to stabilize the disease, establishing a "race against time" that many patients lose.

1.3 The Scientific Rationale for Direct Amyloid-Targeting Strategies

The inherent limitation of SoC therapies created a clear and significant unmet medical need for a complementary therapeutic approach: one that could actively and rapidly clear existing amyloid deposits from organs.[2] Such a therapy, termed an "amyloid depleter," would not replace anti-plasma cell treatment but would be administered alongside it, providing a dual mechanism of action.[11] While the SoC halts the production of new amyloid, the amyloid depleter would work to remove the existing, life-threatening deposits.

This strategy is particularly crucial for high-risk patients. By clearing amyloid, an amyloid-depleting agent could theoretically halt or even reverse organ damage, thereby stabilizing the patient and providing a crucial bridge to allow the long-term benefits of the anti-plasma cell therapy to take effect.[18] The ultimate goal of this combined approach is to improve not just hematologic and organ biomarker responses, but the most important clinical outcome: overall survival. It was precisely this scientific rationale that drove the development of Birtamimab as a potential first-in-class amyloid depleter.

---

Section 2: Birtamimab: Molecular Profile and Pharmacological Mechanism

2.1 Drug Identification and Characteristics

Birtamimab is a biotech drug classified as an investigational humanized monoclonal antibody. Its development was predicated on a sophisticated and rational design intended to specifically target pathological amyloid while actively recruiting the host immune system for its clearance.

The molecular design of Birtamimab was a deliberate strategy to optimize both safety and efficacy. The antibody was engineered to recognize a "cryptic" epitope—a structural feature that is hidden in normally folded light chains but becomes exposed when the proteins misfold and aggregate.[3] This exquisite specificity was intended to ensure that the drug would only bind to the pathological amyloid-forming proteins, thereby avoiding on-target toxicity with the billions of healthy, functional immunoglobulins and light chains circulating in the body. Furthermore, the selection of a humanized IgG1 backbone was a critical choice to maximize the antibody's effector function. The IgG1 isotype is known to bind with high affinity to Fc gamma receptors ($Fc{\gamma}R$) on the surface of phagocytic immune cells like macrophages, making it a potent activator of the body's natural cellular clearance mechanisms.[17] This combination of highly specific targeting and potent immune activation made Birtamimab, on paper, an ideal candidate for an amyloid-depleting therapy.

Table 1: Key Characteristics of Birtamimab

Attribute	Description	Source(s)
Name	Birtamimab	21
Synonyms	NEOD001, ELT1-01, HU2A4	21
DrugBank ID	DB16414	23
Type	Biotech, Monoclonal Antibody	21
CAS Number	1608108-91-3	24
Molecular Weight	Approx. 145.5 - 146.4 kDa	26
Target	Misfolded Amyloid Light Chains (${\kappa}$ and ${\lambda}$), SAA1	21
Mechanism of Action	Amyloid Depleter: Neutralizes soluble toxic aggregates and promotes phagocytic clearance of insoluble amyloid deposits.	1
Backbone	Humanized IgG1	19
Source	Recombinantly expressed in Chinese Hamster Ovary (CHO) cells	24

2.2 Detailed Mechanism of Action (MoA)

Birtamimab was designed to function as an "amyloid depleter" through a dual-action mechanism targeting both soluble and insoluble forms of pathogenic light chains.[1]

1. Neutralization of Soluble Toxic Aggregates: The antibody binds to and neutralizes circulating soluble oligomers of misfolded light chains.[1] These soluble precursors are believed to be directly cardiotoxic and are a key component of the ongoing organ damage in AL amyloidosis. By sequestering these aggregates, Birtamimab was intended to mitigate this direct toxicity.
2. Clearance of Insoluble Amyloid Deposits: The primary mechanism involves the clearance of established, insoluble amyloid fibrils deposited in organs.[5] Birtamimab binds to the conserved epitope on these fibrils, effectively "tagging" them for destruction in a process known as opsonization.[17] The Fc portion of the Birtamimab IgG1 backbone then engages with $Fc{\gamma}$ receptors on macrophages and other phagocytes, triggering them to engulf and degrade the antibody-amyloid complex.[3] This process of macrophage-induced phagocytosis was hypothesized to actively remove the amyloid burden from compromised organs, allowing for potential functional recovery.[2]

This dual mechanism was designed to be complementary to standard-of-care chemotherapy. While chemotherapy reduces the production of new amyloidogenic light chains, Birtamimab was intended to clear the existing pathogenic proteins that were already causing harm.[13]

2.3 Pharmacokinetics and Dosing

Clinical studies established a pharmacokinetic profile for Birtamimab consistent with other therapeutic monoclonal antibodies. In the Phase 1/2 trial, Birtamimab demonstrated slow clearance and a long terminal half-life of approximately 13 to 16 days.[17] This extended half-life, supported by neonatal Fc receptor (FcRn)-mediated recycling, allows for sustained target engagement with an infrequent dosing schedule.[17]

The recommended dose for late-stage clinical trials was determined to be 24 mg/kg administered as an intravenous (IV) infusion every 28 days.[4] This dose was established in early-phase studies where no dose-limiting toxicities were observed up to this level.[17]

A key success of the antibody's design was its low immunogenicity. Birtamimab was humanized from its murine precursor, 2A4, to minimize the risk of patients developing anti-drug antibodies (ADAs). This effort was successful, as no ADAs were detected in the Phase 1/2 clinical trial, reducing concerns about altered clearance or hypersensitivity reactions that can compromise the efficacy and safety of therapeutic antibodies.[17]

---

Section 3: The Clinical Development Pathway: A Tale of Two Phase 3 Trials

The clinical development of Birtamimab was characterized by a dramatic reversal of fortune, moving from a terminated program to a resurrected late-stage asset before its ultimate failure. This trajectory was defined by the conflicting results of two pivotal Phase 3 trials, VITAL and AFFIRM-AL.

3.1 Early Phase Development (Phase 1/2 and PRONTO)

Birtamimab's journey began with standard early-phase clinical trials. A Phase 1/2 study (NCT01707264) in previously treated AL amyloidosis patients with persistent organ dysfunction successfully established the drug's safety and tolerability profile, identifying the 24 mg/kg monthly IV dose for further development.[2]

Following this, Prothena initiated several Phase 2 studies, including the PRONTO study (NCT02632786), a Phase 2b trial in previously treated patients, which was completed.[30] Other Phase 2 trials, such as NCT03168906, were terminated before completion, reflecting the challenges of developing drugs in this complex disease space.[21]

3.2 The VITAL Trial (NCT02312206): Futility, Termination, and a Post-Hoc Signal

The VITAL study was Birtamimab's first major test. It was a large, global, randomized, double-blind, placebo-controlled Phase 3 trial designed to evaluate the efficacy of Birtamimab plus standard of care (SoC) versus placebo plus SoC.[4] The study enrolled 260 newly diagnosed, treatment-naive patients with AL amyloidosis and cardiac involvement.[2] The primary endpoint was a composite of time to all-cause mortality (ACM) or time to centrally adjudicated cardiac hospitalization.[4]

In April 2018, the trial was terminated prematurely.[4] The decision was based on a recommendation from the independent data monitoring committee following a pre-planned interim futility analysis, which concluded that the study was highly unlikely to meet its primary endpoint.[2] The final analysis confirmed this, showing no statistically significant difference between the treatment arms (Hazard Ratio 0.826; 95% Confidence Interval [CI] 0.574-1.189; $p = 0.303$).[4] Following this definitive failure, Prothena halted all development of Birtamimab and underwent significant corporate restructuring, including laying off 57% of its workforce.[33]

The story took an unexpected turn following a post-hoc (non-prespecified) analysis of the VITAL data. Investigators examined outcomes within a small subgroup of 77 patients who had the most severe form of the disease, Mayo Stage IV.[4] In this high-risk group, the analysis revealed a dramatic and statistically significant survival benefit favoring Birtamimab. At 9 months, 74% of Mayo Stage IV patients treated with Birtamimab were alive, compared to only 49% of those who received placebo.[4] This corresponded to a 59% reduction in the relative risk of death (HR 0.413; 95% CI 0.191-0.895; $p = 0.021$).[2] Furthermore, this subgroup also showed statistically significant improvements in quality of life (SF-36 physical component score) and physical functioning (6-minute walk test).[7]

3.3 The AFFIRM-AL Confirmatory Trial (NCT04973137): The Definitive Test

The compelling but statistically tenuous signal from the VITAL post-hoc analysis formed the sole basis for resurrecting the Birtamimab program.[33] Such analyses are widely understood to be hypothesis-generating, not confirmatory, as they are prone to false-positive results arising from chance, particularly in small subgroups. The only way to validate such a finding is with a new, prospective, confirmatory trial designed specifically to test that hypothesis.

Thus, in 2021, Prothena launched the Phase 3 AFFIRM-AL trial.[7] The trial was a global, randomized, double-blind, placebo-controlled study that enrolled 207 newly diagnosed, treatment-naive patients with Mayo Stage IV AL amyloidosis—the exact population in which the post-hoc signal was observed.[6] The trial's design and analysis plan were developed in close collaboration with the FDA under a Special Protocol Assessment (SPA). An SPA signifies the agency's agreement that the trial design is adequate to support a regulatory submission for approval if successful.[7] Reflecting the high unmet need in this patient population, the FDA agreed to a primary endpoint of time to all-cause mortality with a relaxed statistical significance threshold of $p < 0.10$, a lower bar than the conventional $p < 0.05$.[7] This regulatory flexibility provided a clearer path to potential approval but also set the stage for a definitive verdict on the drug's efficacy.

In May 2025, Prothena announced the top-line results: the AFFIRM-AL trial had failed.[5] Birtamimab did not meet its primary endpoint, showing no improvement in time to all-cause mortality compared to placebo (HR 0.915; $p = 0.7680$).[5] The result was not borderline; it was unequivocally negative. The trial also failed to meet its key secondary endpoints, with no significant benefit observed in the 6-minute walk test or the SF-36 quality of life score.[6] In response to this definitive failure, Prothena announced the immediate and final discontinuation of the Birtamimab program.[33]

Table 2: Summary of Major Clinical Trials (PRONTO, VITAL, AFFIRM-AL)

Trial Name (Identifier)	Phase	Patient Population	N	Arms	Primary Endpoint(s)	Status
PRONTO (NCT02632786)	2b	Previously treated AL amyloidosis with persistent cardiac dysfunction	129	Birtamimab vs. Placebo	Cardiac best response (NT-proBNP)	Completed 30
VITAL (NCT02312206)	3	Newly diagnosed, treatment-naive AL amyloidosis with cardiac involvement	260	Birtamimab + SoC vs. Placebo + SoC	Time to all-cause mortality or cardiac hospitalization	Terminated (Futility) 4
AFFIRM-AL (NCT04973137)	3	Newly diagnosed, treatment-naive Mayo Stage IV AL amyloidosis	207	Birtamimab + SoC vs. Placebo + SoC	Time to all-cause mortality	Terminated (Failure) 21

---

Section 4: A Critical Appraisal of Efficacy and Safety

4.1 Analysis of Efficacy: The Irreconcilable Difference

The clinical story of Birtamimab is defined by the stark and irreconcilable difference between the post-hoc analysis of the VITAL trial and the prospective results of the AFFIRM-AL trial. The former suggested a profound, life-saving benefit in the sickest patients, while the latter demonstrated a complete lack of efficacy.

Table 3: Comparative Efficacy Endpoints: VITAL (Post-Hoc Mayo IV Subgroup) vs. AFFIRM-AL

Endpoint	VITAL (Post-Hoc Mayo IV Subgroup, n=77)	AFFIRM-AL (Prospective, n=207)
Time to All-Cause Mortality	HR = 0.413 (95% CI: 0.191-0.895)	HR = 0.915
p-value	$p = 0.021$	$p = 0.7680$
6-Minute Walk Test (6MWT)	+36.37 m improvement vs. placebo	No significant difference
p-value	$p = 0.022$	$p = 0.5288$
SF-36 Physical Component Score	+4.65 point improvement vs. placebo	No significant difference
p-value	$p = 0.046$	$p = 0.9597$

Sources: [4]

In evidence-based medicine, a prospective, randomized, controlled trial designed specifically to test a hypothesis (AFFIRM-AL) provides a much higher level of evidence than a retrospective, non-prespecified analysis of a small subgroup (VITAL post-hoc). Therefore, the results from AFFIRM-AL must be accepted as the definitive and reliable evidence. The conclusion is unambiguous: Birtamimab confers no survival or functional benefit to patients with Mayo Stage IV AL amyloidosis. The highly promising signal from the VITAL trial is best explained as a statistical anomaly, a chance finding that did not hold up to rigorous scientific validation.

4.2 The Complete Safety and Tolerability Profile

In stark contrast to its lack of efficacy, Birtamimab consistently demonstrated an excellent safety and tolerability profile throughout its clinical development program. This conclusion is supported by a pooled analysis of safety data from 302 patients treated across the Phase 1, 2, and 3 trials, including the randomized, placebo-controlled PRONTO and VITAL studies.[14]

Across these studies, Birtamimab was found to be generally safe and well-tolerated, both as a monotherapy and when administered in combination with standard-of-care chemotherapy.[6] The rates of treatment-emergent adverse events (TEAEs), serious TEAEs, and Grade ${\ge}3$ TEAEs were similar between the Birtamimab and placebo arms.[14] This finding is particularly noteworthy given the frail nature of the AL amyloidosis patient population.

Table 4: Pooled Safety Data - Most Common Treatment-Emergent Adverse Events (TEAEs) in PRONTO & VITAL Trials

Adverse Event	Birtamimab Arm (n=196)	Placebo Arm (n=193)
Fatigue	36.2%	34.2%
Diarrhea	33.2%	33.7%
Nausea	31.6%	30.1%
Constipation	31.1%	31.6%
Dyspnea (Shortness of Breath)	25.0%	24.9%

Source: [14]

The most commonly reported serious TEAEs were cardiac disorders, such as cardiac failure, syncope, and cardiac arrest.[14] However, these events were considered to be consistent with the natural progression of the underlying disease in this severely ill population and were not attributed to a specific drug-related toxicity. Furthermore, infusion-associated reactions were infrequent (5.1% in the Birtamimab arm vs. 3.6% in the placebo arm) and were generally mild to moderate in severity.[14]

The clear conclusion from the cumulative safety data is that Birtamimab failed due to a lack of efficacy, not because of safety concerns. This distinction is critical for the field. It suggests that the therapeutic strategy of using a monoclonal antibody to target and clear amyloid deposits is a safe and viable approach. The failure was specific to this molecule's inability to translate that mechanism into a clinical benefit, leaving the door open for other, potentially more effective amyloid-depleting antibodies.

---

Section 5: Regulatory and Corporate Trajectory

5.1 Engagement with Regulatory Agencies

Birtamimab's development was supported by several key regulatory designations intended to expedite the review of drugs for serious, life-threatening conditions. On February 17, 2012, the U.S. FDA granted Birtamimab Orphan Drug Designation for the treatment of both AA amyloidosis and AL amyloidosis.[1] This designation was also granted by the European Medicines Agency (EMA).[2]

Following the promising post-hoc analysis from the VITAL trial, the FDA also granted Birtamimab Fast Track Designation for the treatment of Mayo Stage IV patients with AL amyloidosis to reduce the risk of mortality.[2] This designation facilitates more frequent communication with the agency to expedite development and review.[42]

The most significant regulatory interaction was the agreement with the FDA on a Special Protocol Assessment (SPA) for the confirmatory AFFIRM-AL trial.[7] This agreement provided Prothena with a clear, pre-defined regulatory path, confirming that the trial's design and primary endpoint analysis were sufficient to support a Biologics License Application (BLA) if the results were positive. Despite these supportive designations, the definitive failure of the AFFIRM-AL trial meant that a regulatory submission was never made, and Birtamimab remains an unapproved investigational drug.[40]

5.2 Prothena's Corporate Strategy: A Case Study in High-Risk Development

The development of Birtamimab is a compelling case study in the high-stakes decision-making and strategic risks inherent to clinical-stage biotechnology companies. Prothena, the sole developer of the wholly-owned asset, navigated a tumultuous path defined by failure, hope, and ultimately, a second failure.[41] It should be noted that despite user query implications, there is no evidence of any development partnership between Prothena and Pfizer for the Birtamimab program; Prothena's major collaborations are with companies like Roche, Bristol Myers Squibb, and Novo Nordisk on other pipeline assets.[33]

The corporate trajectory can be summarized in three key phases:

1. The First Discontinuation (2018): Following the VITAL trial's termination for futility, Prothena made the decisive and difficult decision to halt all development of Birtamimab. This was accompanied by a substantial corporate restructuring that included laying off 57% of its employees, a move designed to conserve capital and refocus resources on other pipeline programs.[33]
2. The Resurrection Gamble (2021): In a bold strategic pivot, Prothena resurrected the program in 2021.[33] This decision was based entirely on the strength of the post-hoc survival signal in the VITAL trial's Mayo Stage IV subgroup. This move represented a monumental "biotech bet," staking hundreds of millions of dollars and the company's credibility on the hypothesis that the post-hoc finding was a true signal of efficacy rather than a statistical fluke. The fact that Prothena advanced this high-risk program without a major pharmaceutical partner suggests that external due diligence may have been more skeptical of the signal's robustness, leaving Prothena to shoulder the entire clinical and financial risk.
3. The Final Outcome (2025): The failure of the AFFIRM-AL trial in May 2025 marked the definitive end of the Birtamimab program.[35] Prothena immediately announced the discontinuation of all development and outlined plans for another "substantial reduction in organizational size" to manage costs.[5] The company, which had a cash position of $418.8 million at the end of the first quarter of 2025, initiated a review of its strategic business options in the wake of the failure.[21]

---

Section 6: Conclusion and Future Perspectives

6.1 Key Lessons Learned from the Birtamimab Clinical Program

The Birtamimab development program, from its promising scientific rationale to its definitive clinical failure, offers several invaluable lessons for the field of drug development:

• The Unreliability of Post-Hoc Subgroup Analyses: The primary lesson from Birtamimab's story is the profound risk of making major investment and clinical development decisions based on post-hoc analyses. While such findings can be intriguing and hypothesis-generating, they are not a substitute for prospective, confirmatory evidence. The starkly negative result of the purpose-built AFFIRM-AL trial serves as a powerful, real-world validation of this core principle of clinical science.
• The Challenge of High-Mortality Indications: Demonstrating a statistically significant survival benefit in a patient population with a very high background mortality rate, such as Mayo Stage IV AL amyloidosis, is exceptionally difficult. A therapeutic must have a truly substantial and rapid treatment effect to separate the survival curves meaningfully from placebo in a feasible trial timeframe.
• The Importance of a Clean Safety Profile: A crucial positive takeaway is that the amyloid-depleting antibody approach appears to be safe. Birtamimab's excellent tolerability, even in a frail population receiving concomitant chemotherapy, de-risks the general mechanism of action from a safety perspective and provides confidence for the development of other antibodies in this class.

6.2 The Future of Amyloid-Targeting Therapies in AL Amyloidosis Post-Birtamimab

Despite the disappointing outcome of the AFFIRM-AL trial, the strategic imperative for developing therapies that clear existing amyloid deposits remains as strong as ever.[6] Experts and patient advocacy groups continue to believe that this approach is essential for improving outcomes, particularly for patients with advanced disease.[6] The failure of Birtamimab is viewed not as a failure of the strategy, but as a failure of a specific molecule.

The field is actively pursuing several next-generation approaches:

• Other Anti-Fibril Antibodies: Research continues on other monoclonal antibodies designed to clear amyloid. A leading candidate is anselamimab (formerly CAEL-101), which is also in late-stage clinical development and targets a different epitope on amyloid fibrils.[17] The results of these trials are eagerly awaited.
• Next-Generation Anti-Plasma Cell Immunotherapies: There is growing excitement around novel immunotherapies that can induce even faster and deeper hematologic responses than the current standard of care. These include bispecific T-cell engagers (BiTEs) like teclistimab and elranatamab, and chimeric antigen receptor (CAR) T-cell therapies, which are being investigated in AL amyloidosis after showing remarkable efficacy in multiple myeloma.[48]

The future of AL amyloidosis treatment will likely involve intelligently designed combination therapies. The ideal regimen would combine a highly potent anti-plasma cell therapy to rapidly shut down the production of new light chains with a safe and effective amyloid-depleting agent to clear the existing organ damage.[11]

6.3 Final Expert Assessment

Birtamimab was a rationally designed, safe, but ultimately ineffective therapeutic agent for AL amyloidosis. Its development journey provides a powerful and cautionary case study in the interpretation of clinical trial data, the perils of post-hoc analyses, and the nature of high-risk corporate strategy in the biotechnology sector.

While Birtamimab failed to become a new medicine, the program was not without value. It has provided the field with a large, high-quality dataset that definitively closes the door on this specific molecular approach while simultaneously de-risking the safety profile of its therapeutic class. The lessons learned from Birtamimab's failure will enforce greater scientific rigor in the evaluation of clinical signals and will help shape the development of the next generation of amyloid-depleting therapies. These future therapies, building on the knowledge gained from both the successes and failures of their predecessors, remain a critical source of hope for patients suffering from the devastating consequences of advanced AL amyloidosis.

Works cited

1. The mechanism of action, pharmacological characteristics, and ..., accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/38600883/
2. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial | Blood | American Society of Hematology, accessed October 24, 2025, https://ashpublications.org/blood/article/142/14/1208/496536/Birtamimab-plus-standard-of-care-in-light-chain
3. The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis | Request PDF - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/379752858_The_mechanism_of_action_pharmacological_characteristics_and_clinical_utility_of_the_amyloid_depleter_birtamimab_for_the_potential_treatment_of_AL_amyloidosis
4. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial - PubMed Central, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10644097/
5. Birtamimab Misses Primary Phase 3 Endpoint for AL Amyloidosis - HCPLive, accessed October 24, 2025, https://www.hcplive.com/view/birtamimab-misses-primary-phase-3-endpoint-for-al-amyloidosis
6. Prothena Announces Negative AFFIRM-AL Trial Results - Amyloidosis Research Consortium, accessed October 24, 2025, https://arci.org/negative-affirm-al-results/
7. Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study. - ASCO Publications, accessed October 24, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS8076
8. AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review - PMC - PubMed Central, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8543128/
9. LIGHT CHAIN AMYLOIDOSIS (AL AMYLOIDOSIS) - Amyloidosis Research Consortium, accessed October 24, 2025, https://arci.org/wp-content/uploads/2021/02/Treatment-Overview_AL-Amyloidosis.pdf
10. AL Amyloidosis: Current Treatment and Outcomes - PMC - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11991823/
11. Future Developments in the Treatment of AL Amyloidosis - MDPI, accessed October 24, 2025, https://www.mdpi.com/2673-6357/3/1/12
12. Immunoglobulin-Related Amyloidosis Treatment & Management - Medscape Reference, accessed October 24, 2025, https://emedicine.medscape.com/article/208839-treatment
13. What is Birtamimab used for? - Patsnap Synapse, accessed October 24, 2025, https://synapse.patsnap.com/article/what-is-birtamimab-used-for
14. Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis | Blood | American Society of Hematology, accessed October 24, 2025, https://ashpublications.org/blood/article/142/Supplement%201/3409/499195/Pooled-Analysis-of-Safety-from-Birtamimab-Phase-1
15. A9000924PT Birtamimab Patient Infographic_Digital Layout_v4.1_SM, accessed October 24, 2025, https://arci.org/wp-content/uploads/2024/02/PRTA-MRC00143_Oct-2023_Birtamimab-Patient-Infographic-Digital-Version.pdf
16. Birtamimab Patient Infographic_Updated Digital Version_v0.1_RM - Prothena, accessed October 24, 2025, https://www.prothena.com/wp-content/uploads/2024/03/1Birtamimab-Patient-Infographic_Digital-Version_for-Corp-Website_13Mar2024.pdf
17. Full article: The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis, accessed October 24, 2025, https://www.tandfonline.com/doi/full/10.1080/10428194.2024.2337803
18. Is birtamimab an option for patients with advanced AL amyloidosis at high risk for early death? - Multiple Myeloma Hub, accessed October 24, 2025, https://multiplemyelomahub.com/medical-information/is-birtamimab-an-option-for-patients-with-advanced-al-amyloidosis-at-high-risk-for-early-death
19. ashpublications.org, accessed October 24, 2025, https://ashpublications.org/blood/article/142/14/1208/496536/Birtamimab-plus-standard-of-care-in-light-chain#:~:text=Birtamimab%20(formerly%20NEOD001)%2C%20an,amyloid%20via%20macrophage%2Dinduced%20phagocytosis.
20. Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma, accessed October 24, 2025, https://ir.prothena.com/investors/press-releases/news-details/2024/Prothena-Announces-Review-on-Birtamimab-Mechanism-of-Action-and-Pharmacological-Characteristics-Published-in-Leukemia--Lymphoma/default.aspx
21. Global Drug Intelligence Database - Synapse, accessed October 24, 2025, https://synapse.patsnap.com/drug/7affc6cce2294c3a8a2d1eaab9dae762
22. Birtamimab - CymitQuimica, accessed October 24, 2025, https://cymitquimica.com/products/TM-T76931/1608108-91-3/birtamimab
23. Birtamimab Terminated Phase 2 Trials for Amyloidosis Treatment | DrugBank Online, accessed October 24, 2025, https://go.drugbank.com/drugs/DB16414/clinical_trials?conditions=DBCOND0013362&phase=2&purpose=treatment&status=terminated
24. Birtamimab | Abbexa Ltd, accessed October 24, 2025, https://www.abbexa.com/birtamimab
25. HY-P99481-10mg by MedChemexpress LLC - Insight Biotechnology, accessed October 24, 2025, https://www.insightbio.com/productinfo/HY-P99481-10mg/MedChemexpress%20LLC
26. Birtamimab (NEOD001) | Anti-Amyloid Antibody - MedchemExpress.com, accessed October 24, 2025, https://www.medchemexpress.com/birtamimab.html
27. Birtamimab (Anti-Amyloid Alpha) - Selleck Chemicals, accessed October 24, 2025, https://www.selleckchem.com/products/birtamimab-anti-amyloid-alpha.html
28. Birtamimab Pushes the Needle in AL Amyloidosis - OncLive, accessed October 24, 2025, https://www.onclive.com/view/birtamimab-pushes-the-needle-in-al-amyloidosis
29. Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis | Request PDF - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/376165746_Pooled_Analysis_of_Safety_from_Birtamimab_Phase_1-3_Studies_in_Patients_with_Light_Chain_AL_Amyloidosis
30. Birtamimab Completed Phase 2 Trials for Primary Amyloidosis Treatment | DrugBank Online, accessed October 24, 2025, https://go.drugbank.com/drugs/DB16414/clinical_trials?conditions=DBCOND0040057&phase=2&purpose=treatment&status=completed
31. NCT02312206 | The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis | ClinicalTrials.gov, accessed October 24, 2025, https://clinicaltrials.gov/study/NCT02312206
32. Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/37366170/
33. Prothena reburies drug after 2nd swing at rare disease misses, accessed October 24, 2025, https://www.fiercebiotech.com/biotech/prothena-reburies-drug-after-second-swing-rare-disease-misses-plans-substantial-layoffs
34. NCT04973137 | A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis | ClinicalTrials.gov, accessed October 24, 2025, https://clinicaltrials.gov/study/NCT04973137
35. Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint, accessed October 24, 2025, https://ir.prothena.com/investors/press-releases/news-details/2025/Prothena-Announces-Phase-3-AFFIRM-AL-Clinical-Trial-for-Birtamimab-in-Patients-with-AL-Amyloidosis-Did-Not-Meet-Primary-Endpoint/default.aspx
36. Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA - GlobeNewswire, accessed October 24, 2025, https://www.globenewswire.com/news-release/2021/02/01/2167691/0/en/Prothena-Announces-Confirmatory-Phase-3-AFFIRM-AL-Study-of-Birtamimab-in-Mayo-Stage-IV-Patients-with-AL-Amyloidosis-under-SPA-Agreement-with-FDA.html
37. Prothena discontinues birtamimab development and announces corporate restructuring, accessed October 24, 2025, https://www.alzheimer-europe.org/news/prothena-discontinues-birtamimab-development-and-announces-corporate-restructuring
38. Birtamimab Terminated Phase 3 Trials for Primary Amyloidosis Treatment | DrugBank Online, accessed October 24, 2025, https://go.drugbank.com/drugs/DB16414/clinical_trials?conditions=DBCOND0040057&phase=3&purpose=treatment&status=terminated
39. Paper: Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis, accessed October 24, 2025, https://ash.confex.com/ash/2023/webprogram/Paper174703.html
40. Search Orphan Drug Designations and Approvals - FDA, accessed October 24, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=361411
41. Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs, accessed October 24, 2025, https://ir.prothena.com/investors/press-releases/news-details/2024/Prothena-Provides-Updates-on-PRX012-PRX123-Birtamimab-and-Portfolio-Programs/default.aspx
42. Fast Track | FDA, accessed October 24, 2025, https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
43. AL-Amyloidosis Backgrounder | Prothena, accessed October 24, 2025, https://www.prothena.com/al-amyloidosis-backgrounder/
44. Read Our Publications On Birtamimab, Prasinezumab And More, accessed October 24, 2025, https://www.prothena.com/our-science/publications/
45. Neurodegenerative & Rare Peripheral Amyloid Disease Pipeline, accessed October 24, 2025, https://www.prothena.com/pipeline/
46. Results of the Phase III AFFIRM-AL trial of birtamimab in AL amyloidosis - YouTube, accessed October 24, 2025, https://www.youtube.com/watch?v=kRcoL5yIms0
47. Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101, accessed October 24, 2025, https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025016731/546231/Long-term-follow-up-of-patients-with-AL
48. Debulking AL Amyloidosis – One Fibril at a Time | Dana-Farber Cancer Institute, accessed October 24, 2025, https://www.dana-farber.org/for-physicians/clinical-resources/hematologic-malignancies/advances-newsletter/2025-issue-20/debulking-al-amyloidosis
49. Immune Therapies in AL Amyloidosis—A Glimpse to the Future - PMC, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11048972/